Full Breakdown
FDA Approves Gilead’s Bixlenvo: A Once-Daily Two-Drug HIV Regimen
8/29/2026, 7:56:06 AM
Core Approval Event
On August 27, 2026, the U.S. Food and Drug Administration (FDA) granted approval for Bixlenvo™ (bictegravir 75 mg/lenacapavir 50 mg), a single-tablet regimen (STR) for adults whose HIV-1 viral load is already suppressed (< 50 copies/mL). Patients begin with a two-day loading dose of oral lenacapavir (Sunlenca) alongside Bixlenvo, then continue with one Bixlenvo tablet daily.
Background & Context
Gilead’s HIV portfolio includes bictegravir-based products such as Biktarvy. Lenacapavir, marketed as Sunlenca for multidrug-resistant HIV and as Yeztugo for prevention, expands Gilead’s capsid-inhibitor line. The new STR targets roughly 5 % of U.S. people living with HIV who remain on multi-pill regimens because of resistance or intolerance to existing STRs.
Data & Statistics
- Wholesale acquisition cost: $4,595 for a 30-day supply.
- Trial enrollment: 557 adults in ARTISTRY-1 (15 countries) and 574 adults in ARTISTRY-2. Median ages were 60 y (ARTISTRY-1) and 49 y (ARTISTRY-2).
- Efficacy at week 48: 94 %–96 % maintained undetectable viral loads, comparable to prior complex regimens (ARTISTRY-1) or to Biktarvy (ARTISTRY-2).
- Virologic failure: 0.8 % (3/557) in ARTISTRY-1 and 1.3 % (5/574) in ARTISTRY-2 versus 1.1 % and 1.0 % in comparator arms.
- Safety: Headache (4 %), nausea (3 %), diarrhea (2 %) were most common. Drug-related events occurred in 14 % of Bixlenvo participants versus 2 % on complex regimens (ARTISTRY-1). One hepatitis B reactivation was noted.
- Patient-reported outcomes: Switchers reported higher treatment satisfaction.
Official Statements & Responses
The FDA’s approval letter noted that Bixlenvo met statutory criteria for safety and efficacy in virologically suppressed adults with no known resistance to either component. Gilead described the product as the “smallest once-daily STR” for this segment, emphasizing its potential to improve adherence.
Why It Matters
The regimen consolidates two agents into a single tablet, reducing pill burden for patients with extensive treatment histories. Commercially, Bixlenvo expands Gilead’s HIV franchise as competitors such as Merck introduce similar two-drug pills (e.g., Idvynso). Gilead also announced a collaboration with Merck on a once-weekly lenacapavir/islatravir pill, indicating a shift toward longer-acting oral options.
Conflicting Reports & Gaps
Efficacy percentages vary slightly across the two Phase III trials (94 %–96 % vs. 94 % vs. 91 % in comparator arms), reflecting differences in study populations but all supporting non-inferiority. The higher rate of drug-related adverse events in ARTISTRY-1 (14 % vs. 2 %) contrasts with the similar safety profile reported in ARTISTRY-2, suggesting tolerability may differ by baseline regimen complexity. Long-term outcomes beyond 48 weeks remain unreported.
Verbatim Quotes
- “The main advantage of this combination is ?that it potentially offers a simpler option, in terms of pill burden, to patients who might currently be on more complex regimens due to a history of drug resistant virus,” — Monika Shah, infectious disease specialist, Memorial Sloan Kettering Cancer Center
- “Bixlenvo offers a new once-daily single-tablet regimen designed for the evolving needs of people with HIV,” — Chloe Orkin, MD, Queen Mary University of London
What’s Next
Gilead plans to launch Bixlenvo within days of approval, targeting patients on complex multi-pill regimens. The company will monitor real-world adherence and safety data as the product enters the market, while continuing development of weekly oral formulations with Merck.
